β-Glucan, a “Specific” Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 (CD11b/CD18)

J Immunol September 15, 1999, 163 (6) 3045-3052;Yan J Immunol 1999 — Article shows that beta glucan enhances tumor targeting by immune cells when used with certain antibodies. Article also describes beta glucan’s role in  (modifying) cancer tumor cells with an iC3b...

β-Glucan-Binding Lectin Site of Mouse CR3 (CD11b/CD18) and Its Function in Generating a Primed State of the Receptor That Mediates Cytotoxic Activation in Response to iC3b-Opsonized Target Cells

J Immunol February 15, 1999, 162 (4) 2281-2290; Xia JI 1999 – Article examines the similarities of human and mouse complement receptor 3 (CR3) and describes how beta glucan binds to the Lectin site of the CR3 thereby causing a broad immune response.  Read...